Genmab — Januar 2017
-
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. https://clinicaltrials.gov/ct2/show/NCT03011034?term=daratumumab&rank=15&submit_fld_opt=
-
Genmab X5 er et Vontobel produkt - BULL GENM X5 VON.
-
Handles på Stockholmbørsen som lukkede kl 13:00 i dag, og derfor er kursen ikke opdateret - så der venter en lille "gevinst" i morgen tidlig

-
Det lykkedes Bud..Godt gået.

-
God morgen. Nyt phase 2 studie med Dara fra Janssen. Myoplastisk syndrom et forstadie til blod cancer. https://www.clinicaltrials.gov/ct2/show/NCT03011034?term=NCT03011034&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind